Last updated on February 2020

Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Brief description of study

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Clinical Study Identifier: NCT03126110

Find a site near you

Start Over

University of Florida

Gainesville, FL United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Fox Chase Cancer Center

Philadelphia, PA United States
  Connect »

MD Anderson

Houston, TX United States
  Connect »

Austin Hospital

Heidelberg, Australia
  Connect »

CHU Brugmann

Bruxelles, Belgium
  Connect »

AZ Groeninge

Kortrijk, Belgium
  Connect »